Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 964.99B | 827.70B | 755.41B | 726.42B | 684.40B |
Gross Profit | 188.31B | 168.72B | 151.45B | 145.11B | 134.98B |
EBITDA | 53.74B | 47.50B | 44.91B | 46.93B | 42.66B |
Net Income | 24.45B | 23.80B | 23.16B | 27.16B | 21.43B |
Balance Sheet | |||||
Total Assets | 476.55B | 420.97B | 363.05B | 341.32B | 320.28B |
Cash, Cash Equivalents and Short-Term Investments | 52.30B | 45.93B | 37.36B | 55.11B | 52.12B |
Total Debt | 34.06B | 18.20B | 9.41B | 10.44B | 12.12B |
Total Liabilities | 245.10B | 209.90B | 172.54B | 170.74B | 174.61B |
Stockholders Equity | 231.44B | 211.07B | 190.51B | 170.58B | 145.68B |
Cash Flow | |||||
Free Cash Flow | -635.00M | 7.80B | -11.30B | 1.81B | 39.51B |
Operating Cash Flow | 55.17B | 54.43B | 32.19B | 27.88B | 65.46B |
Investing Cash Flow | -57.33B | -49.11B | -43.72B | -19.38B | -26.96B |
Financing Cash Flow | 8.53B | 3.25B | -6.22B | -5.51B | -5.41B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
76 Outperform | ¥423.01B | 22.95 | 0.35% | 14.79% | 35.84% | ||
75 Outperform | ¥691.52B | 16.15 | 16.26% | 0.95% | 20.18% | 82.36% | |
74 Outperform | ¥544.53B | 29.67 | 1.38% | 7.43% | -24.81% | ||
74 Outperform | $534.11B | 17.38 | 11.61% | 2.85% | 6.66% | 5.56% | |
71 Outperform | ¥554.59B | 25.40 | 4.93% | 2.35% | 4.63% | -47.30% | |
70 Neutral | ¥734.15B | 23.60 | 0.70% | 6.96% | 18.31% | ||
65 Neutral | ¥351.06B | 11.13 | -2.99% | 2.50% | 11.77% | -10.16% |
COSMOS Pharmaceutical Corporation reported a significant increase in its financial performance for the nine months ending February 28, 2025, with net sales rising by 5.2% and operating profit increasing by 33.2% compared to the previous period. The company’s improved financial results reflect a robust operational strategy, enhancing its market position and potentially benefiting stakeholders through increased profitability and shareholder value.